DUBLIN–(BUSINESS WIRE)–The “Exportin 1 – Drugs In Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Exportin 1 – Drugs In Development, 2021, outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively.
Furthermore, this report also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
- The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics
Key Topics Covered:
- Introduction
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Overview
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Development
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Assessment
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Companies Involved in Therapeutics Development
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Drug Profiles
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Dormant Products
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Discontinued Products
- Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Product Development Milestones
- Appendix
Companies Mentioned
- Biogen Inc
- CanBas Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Karyopharm Therapeutics Inc
- Oita University Institute of Advanced Medicine Inc
- Wigen Biomedicine Technology (Shanghai) Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u2y0rz
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900